Healio

Subcutaneous adjuvant regimen for breast cancer reduces ‘time toxicity’ of treatment

Please provide your email address to receive an email when new articles are posted on . Subcutaneous administration of a breast cancer therapy significantly decreased treatment time compared with IV ...
Nasdaq

European Commission approves Roche’s Phesgo (fixed-dose combination of Perjeta and Herceptin for subcutaneous injection) for people with HER2-positive breast cancer

Subcutaneous administration is preferred by patients, physicians and healthcare providers, and is associated with a reduction in healthcare costs1,2,3 Treatment with Phesgo is over 90% faster, ...
Nasdaq

Roche’s subcutaneous injection of Tecentriq recommended by the EU’s CHMP for multiple cancer types

Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...
Pharmabiz

Chugai obtains Japanese approval for Phesgo, the fixed-dose subcutaneous combination of Perjeta & Herceptin for HER2-positive breast and colorectal cancer

Chugai Pharmaceutical Co., Ltd. announced that it has obtained regulatory approval from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo combination for subcutaneous injection MA, IN ...
ascopubs.org

Subcutaneous trastuzumab therapy for HER2-positive early breast cancer in the routine clinical practice: First interim analysis of the National Non-Interventional Study (NIS ...

Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease? This is an ASCO Meeting Abstract from the 2016 ASCO Annual ...
The American Journal of Managed Care

Subcutaneous Trastuzumab Induces Immune Function in HER2+ Breast Cancer

Targeted Oncology ™ originally published this article. This version has been lightly edited. Subcutaneous (SC) trastuzumab induced stromal tumor infiltrating lymphocyte (sTIL) enrichment and favorably ...
MedPage Today

Adrienne Waks, MD, on Subcutaneous vs IV Trastuzumab/Pertuzumab in Breast Cancer

Subcutaneous administration of trastuzumab/pertuzumab could save breast cancer patients and healthcare providers substantial amounts of time compared with intravenous ...
Business Wire

Genentech’s Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...
Pharmabiz

Chugai files NDA in Japan for fixed-dose subcutaneous combination of pertuzumab & trastuzumab for HER2-positive breast and colorectal cancer

Chugai Pharmaceutical Co., Ltd. announced that it filed a new drug application for RG6264 with the Ministry of Health, Labour and Welfare (MHLW) for the treatment of HER2-positive breast cancer, and ...
News Medical

New subcutaneous treatment reduces pain, increases survival chances of breast cancer patients

Breast cancer treatments are usually painful, time consuming and aggressive, which leads to long term hospitalization, medical staff and high economic expenses. To fight this problem there is a new ...
FiercePharma

With FDA approval, Roche's blood cancer bispecific Lunsumio goes subcutaneous

Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio amid competition among CD20xCD3 bispecific antibodies. The FDA has approved ...
ascopubs.org

Pharmaco-economic assessment of subcutaneous compared to intravenous trastuzumab in HER2-positive breast cancer patients: A single institution experience.

Real-world healthcare resource utilization and costs among relapsed/refractory (R/R) mantle cell lymphoma (MCL) patients receiving ibrutinib or chemoimmunotherapy (CIT). This is an ASCO Meeting ...